Low Dose Ara-C for Myelodysplastic Syndromes: is it Still a Current Therapy?
- 26 August 2004
- journal article
- review article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 45 (8), 1531-1538
- https://doi.org/10.1080/10428190310001653727
Abstract
The myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with severe cytopenias, leading to serious morbidity, and acute leukemia development. MDS typically occur in elderly people, with a median age at diagnosis ranging between 60 and 75 years. The patients' prognosis, estimated according to the International Prognostic Scoring System, age and performance status should be considered before choosing among the various treatment options. A therapeutic dilemma exists in MDS, due to the multifactorial pathogenetic features of the disease, the heterogeneous stage and the elderly age of patients at diagnosis. This is underlined by the absence of a Food and Drug Administration-approved agent with an indication for this disease. The therapeutic end-points vary from symptom management (using low-intensity treatment with biological targeted agents, or only supportive therapy), to attempts to change the natural history of the disease (generally using high intensity treatment, including intensive chemotherapy and hemopoietic stem cell transplantation). The main goal of low-intensity therapies is generally to induce hematological improvements and is mainly used for low-risk disease. On the other hand, high-intensity therapies generally aims to alter the disease's natural history (improving survival, and decrease progression to acute myeloid leukemia), and are mainly used for high-risk disease. This review will focus on the current role of low-dose Ara-C therapy in the management of MDS. In fact, there is evidence that low-dose chemotherapy with Ara-C can induce responses in patients with MDS. In particular, the use in combinations with growth factors, such as G-CSF or M-CSF, looks promising, suggesting further investigations about this old new therapeutic tool.Keywords
This publication has 23 references indexed in Scilit:
- Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidineBritish Journal of Haematology, 2001
- The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup studyAnnals of Hematology, 1992
- A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemiaBritish Journal of Haematology, 1992
- A randomized trial of 13‐cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndromeBritish Journal of Haematology, 1987
- VERY-LOW-DOSE CYTARABINE FOR MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKAEMIA IN THE ELDERLYThe Lancet, 1986
- Low‐dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemiaAmerican Journal of Hematology, 1985
- CYTARABINE IN PRE-LEUKAEMIAThe Lancet, 1984
- Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose CytarabineNew England Journal of Medicine, 1983
- DIFFERENTIATION OF MYELOID LEUKAEMIC CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1979
- THE DIFFERENTIATION OF MYELOID LEUKAEMIA CELLS: NEW POSSIBILITIES FOR THERAPYBritish Journal of Haematology, 1978